Since early this year, Kerendia has been covered by reimbursement in clinical practices in South Korea.

Kerendia's indication may expand to hypertension as it becomes available for prescriptions at clinical practices.

According to the pharmaceutical industry on August 13th, Kerendia (finerenone) is now being used in clinical practices after obtaining reimbursement coverage in February for adult patients with chronic kidney disease who have type 2 diabetes.

Kerendia is the first non-steroidal, selective mineralocorticoid receptor antagonist and a novel therapeutic approach targeting inflammation and fibrosis in adult chronic kidney disease patients with type 2 diabetes.